Hsbc Holdings PLC Raises Stake in Repligen Corporation $RGEN

Hsbc Holdings PLC grew its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 844.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 19,772 shares of the biotechnology company’s stock after buying an additional 17,679 shares during the period. Hsbc Holdings PLC’s holdings in Repligen were worth $2,308,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Measured Wealth Private Client Group LLC purchased a new stake in shares of Repligen in the third quarter worth $29,000. Bayforest Capital Ltd bought a new position in Repligen in the 4th quarter worth about $32,000. Rachor Investment Advisory Services LLC purchased a new stake in shares of Repligen in the 4th quarter valued at about $33,000. Los Angeles Capital Management LLC bought a new stake in shares of Repligen during the 4th quarter valued at about $36,000. Finally, Farther Finance Advisors LLC grew its holdings in shares of Repligen by 61.8% during the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 128 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Repligen

In other Repligen news, CFO Jason K. Garland sold 733 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the sale, the chief financial officer owned 19,359 shares in the company, valued at approximately $2,807,055. The trade was a 3.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on RGEN. JPMorgan Chase & Co. lowered their target price on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Benchmark raised shares of Repligen from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a report on Tuesday, July 7th. Barclays upped their target price on shares of Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Roth Capital started coverage on Repligen in a research report on Friday, April 17th. They set a “buy” rating and a $160.00 price target on the stock. Finally, Wolfe Research started coverage on Repligen in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $165.36.

Repligen Price Performance

Shares of Repligen stock opened at $131.96 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20. Repligen Corporation has a 52-week low of $100.99 and a 52-week high of $175.77. The company has a fifty day moving average of $131.68 and a 200-day moving average of $132.60. The stock has a market capitalization of $7.44 billion, a price-to-earnings ratio of 146.62, a price-to-earnings-growth ratio of 2.54 and a beta of 1.06.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company had revenue of $194.25 million for the quarter, compared to analysts’ expectations of $192.05 million. During the same quarter last year, the company earned $0.39 EPS. The firm’s revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Equities research analysts expect that Repligen Corporation will post 1.99 EPS for the current year.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.